NBY Novabay Pharmaceuticals Inc.
- 0 P/E
- 25.02 P/S
- 4.68 P/B
- -0.317 EPS
- -2,345.19% Cash ROIC
- 3.60 Cash Ratio
- 0 / 0% Dividend
- 130,539.00 Avg. Vol.
- 38.18M Shares
- 27.9M Market Cap.
NovaBay Pharmaceuticals Inc., a clinical stage biotechnology company, engages in developing proprietary and patented topical Aganocide compounds for the treatment and prevention of various infections without causing bacterial resistance. Its Aganocide compounds are synthetic anti-infective product candidates with equivalent activity to the active antimicrobial molecules generated within white bloo...
Insurance News Net - Feb 20, 2015
The Legacy - Feb 26, 2015
GlobeNewswire (press release) - Mar 20, 2014
Seeking Alpha - Jan 7, 2015
Seeking Alpha - Dec 9, 2013
GlobeNewswire (press release) - Nov 12, 2014
Ticker Report - Feb 13, 2015
The Wall Street Transcript - Jan 26, 2015
GlobeNewswire (press release) - Dec 2, 2013
Business Wire (press release) - Oct 27, 2014